Literature DB >> 11167828

Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance.

H Gregersen1, J Ibsen, L Mellemkjoer, J Dahlerup, J Olsen, H T Sørensen.   

Abstract

To evaluate the mortality and causes of death in monoclonal gammopathy of undetermined significance (MGUS), we identified 1324 cases of MGUS in the period 1978-93 in North Jutland County, Denmark. Data on mortality were obtained by record linkage to the Danish Death Registry. There were 868 deaths in the MGUS cohort during 7785 years of follow-up vs. 409.6 expected, giving a standardized mortality ratio (SMR) of 2.1 (95% confidence interval 2.0-2.3). Malignant transformation was the cause of death in 97 patients vs. 4.9 expected, yielding a SMR of 20.0 (16.2-24.4), which explained about 20% of the excess mortality in the cohort. The mortality was increased for several other malignant and non-malignant causes of death during the first 4 years of follow-up. For late follow-up, 5-18 years after detection of the M-component, the overall SMR was 1.7 (1.5-1.9), and malignant transformation was the only cause of death with a substantial increase of SMR. Although malignant transformation is an important cause of death in MGUS patients, it did not entirely explain the increased mortality. MGUS patients often suffer from coexisting clinical conditions that increase the mortality, especially during the first years after detection of the M-component.

Entities:  

Mesh:

Year:  2001        PMID: 11167828     DOI: 10.1046/j.1365-2141.2001.02533.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 2.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 3.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

4.  The significance of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Shaji Kumar
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 5.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

6.  Risk factors for monoclonal gammopathy of undetermined significance: a systematic review.

Authors:  Maira A Castaneda-Avila; Christine M Ulbricht; Mara Meyer Epstein
Journal:  Ann Hematol       Date:  2021-01-08       Impact factor: 3.673

7.  Curcumin for the prevention of progression in monoclonal gammopathy of undetermined significance: A word of caution.

Authors:  A J M Vermorken; J Zhu; W J M VAN DE Ven; Y Cui; J P Fryns
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

8.  Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.

Authors:  Johanna Karlsson; Björn Andréasson; Nahid Kondori; Evelina Erman; Kristian Riesbeck; Harriet Hogevik; Christine Wennerås
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

9.  Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul W Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  Using pathology-specific laboratory profiles in clinical pathology to reduce inappropriate test requesting: two completed audit cycles.

Authors:  Roberto Baricchi; Michele Zini; Maria Grazia Nibali; Walter Vezzosi; Vincenzo Insegnante; Clotilde Manfuso; Alessandra Polese; Valmer Costoli; Antonio Spelti; Debora Formisano; Danilo Orlandini; Fausto Nicolini; Antonio Poli
Journal:  BMC Health Serv Res       Date:  2012-07-03       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.